The announcement of Pfizer’s newly developed vaccine trial success rate may allow the public to be more accepting of getting the vaccine, director of the National Institute of Allergy and Infectious Diseases (NIAID) said.
In previous cases, when first-generation vaccines were developed, they had 50 to 60 percent efficacy rates—even then, when the public took the vaccines, the other 40 to 50 percent of the people might be immune to the vaccine, and for these people, it wouldn’t be effective, Fauci said.
However, this time it would be different, seeing that the first-generation drug developed for the CCP Virus has more than a 90 percent efficacy and success rate.
“What we’re hoping is that those who have vaccine hesitancy, who are skeptical about a vaccine, will see that the efficacy of this is so high that they may change their mind about wanting to get vaccinated,” Fauci said.
Fauci also brought up vaccines developed by other companies that are very similar to that of the one developed in Pfizer, saying that although they haven’t gone through the evaluation yet, there’s a chance they may also have similar efficacy and success rates.
This meant that should the other vaccines prove to be just as effective and safe as Pfizer’s product, such as the one being developed by Moderna, then there would be two vaccines out there for the public to take to protect themselves from the virus.
“We have the capability—what science has done in an unprecedented way—if this were 15 or 20 years ago, it would have taken a few years to get to where we are now,” Fauci said.
Johnson, who has already ordered several million doses of the Pfizer vaccine, said that the trial data and findings need to be peer-reviewed before the vaccine can be approved.
